Freya Biosciences Advances Lead Microbiome Therapy FB301 Into Phase 2, Boosts Scientific and Leadership Profile

Freya Biosciences reported positive Phase 1 data for its lead microbiome therapy FB301, targeting IVF-related embryo implantation failure. The candidate was safe and well tolerated across all dosing cohorts, and showed clear vaginal microbiome modulation with increased levels of key Lactobacillus species.

The study met its primary and secondary endpoints, including proof-of-concept on shifting dysbiotic microbiomes toward a Lactobacillus-dominant profile. In the highest-dose group, 50% of participants converted to a non-dysbiotic state at six months versus 11.1% on placebo, supporting the drug’s proposed mechanism in reproductive health.

On the back of these results, Freya is advancing FB301 into Phase 2 trials in the U.S. and Germany in women undergoing assisted reproductive technologies, including frozen embryo transfer, and in a bacterial vaginosis population. The asset is now Phase 2-ready under cleared IND and CTA approvals, positioning the company in large, underserved women’s health markets.

The data are also seen internally as validation of Freya’s Dyscover platform, which uses multi-omics and a biobank to design microbiome-based interventions addressing immune dysregulation. A focused pipeline is being built around FB301 and additional first-in-class candidates for IVF failure and preterm birth, although success still depends on later-stage efficacy and regulatory outcomes.

Beyond clinical progress, CEO Colleen Acosta was named one of In Vivo’s 2026 Rising Leaders, boosting leadership visibility in a competitive women’s health and immunology arena. This recognition may support future partnerships, recruitment and financing, even though no direct financial milestones were announced.

Freya is also elevating its scientific profile at the 3rd Microbiome PT Summit in Lisbon, where its chief scientific officer will moderate and chair key sessions on microbiome interventions and citizen science. The company’s active role at the summit underlines its efforts to build credibility and deepen relationships with key opinion leaders and potential collaborators.

Collectively, the week’s developments strengthen Freya Biosciences’ clinical, scientific and leadership positioning in microbiome-based women’s health, while underscoring that its lead program remains in early-stage development with significant execution and regulatory milestones still ahead.